ILT, I certainly hope you're right, but this isn't AdamF's first rodeo, he's put down all sorts of companies and products. He's been right about certain products not achieving approval, however we'll never know if those products may have achieved approval with a different trial because AdamF did so much damage to the companies financially that they couldn't afford further trials and in fact many went out of business.
I frankly believe that many abandoned drugs could be approved, but billions were needed to do so, and they were abandoned. I also believe the opposite may be the case in some companies, CVM for example. Many years ago I made a small investment in it, at that time they actually made their stock symbol HIV and they were targeting AIDS. The drug they were targeting it with is identical with what they're still in trials with, and have been in numerous other diseases. In short each time a trial fails they find a new target to try, all they need is a good find and replace program to change diseases in the multiple press releases they've developed and they're off and running at a new target disease. I think AdamF has gone after them in the past, and perhaps it's one company that deserves to be put out of business, but they keep issuing those PR's and they keep issuing new shares, and they just keep going. I think the son of the old CEO may have taken over from his father. They have Multikine and the regulators have been shown that it's safe, they can take it into new Phase 3 trials for new targets as they wish, it's their money and the regulators won't stop them from spending it as long as patients get SOC treatment plus Multikine and the company is paying for it. Multikine is a cure in search of its disease, perhaps some day it will find it. Meanwhile all sort of other drugs have been abandoned, often after a trial in pancreatic cancer in spite of evidence that it would be far more effective against the likes of colon cancer. They can't afford the colon cancer trial as it's a slow growing cancer and would require a far bigger, longer, and more expensive trial as it's already not nearly as deadly.
I firmly believe that the regulators and drug developers need to find a way to bring trial costs down. I believe that EUA's would provide that sort of vehicle if once efficacy is demonstrated in Phase 1/2 and EUA permitted sale of the product as data was being gathered to result in full approval. Progress toward approval would need to be demonstrated regularly to keep the EUA in force, but as long as that was the case the product could be sold with every use of it tracked. If such a program were available, DCVax-L would have been available to those with GBM for well over a decade.
Gary
Market Data 
Markets 
AI
